- Home
- LFCR vs IRWD Comparison
LFCR vs IRWD Comparison
Compare LFCR & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFCR | IRWD |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.0M | 251.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | LFCR | IRWD |
|---|---|---|
| Price | $8.30 | $3.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $6.00 | $5.34 |
| AVG Volume (30 Days) | 172.3K | ★ 2.6M |
| Earning Date | 01-02-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $128,867,000.00 | ★ $338,987,000.00 |
| Revenue This Year | $2.80 | N/A |
| Revenue Next Year | $11.51 | $4.01 |
| P/E Ratio | ★ N/A | $18.13 |
| Revenue Growth | ★ 0.47 | N/A |
| 52 Week Low | $4.76 | $0.53 |
| 52 Week High | $8.85 | $4.78 |
Technical Indicators
Market Signals| Indicator | LFCR | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 49.50 |
| Support Level | $7.85 | $3.08 |
| Resistance Level | $8.77 | $3.35 |
| Average True Range (ATR) | 0.36 | 0.25 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 63.64 | 16.88 |
Price Performance
Historical ComparisonAbout LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.